DocumentsDate added
Research article:-
*1Kshitiz Ranka,2Ruchita Jain & 3Ankur Jhanwar
Affiliation:-
1Department of Surgery,Kasturba medical college, Mangalore, Karnataka, India.
2Department of Obs & gynae. S.N. Medical College, Jodhpur, Rajasthan, India.
3Department of Surgery, Kota medical college, Rajasthan, India.
Author contributions: - All authors contributed equally to this paper.
Place of study: - Department of Surgery, Kasturba medical college, Mangalore, Karnataka, India.
Abstract:
Introduction: Gastric outlet obstruction (G.O.O.) also known as pyloric obstruction is not a single entity. It is the clinical & patho-physiological consequence of any disease process that produces a mechanical impediment to gastric emptying.
Material& methods: 40 patients attending surgical out-patient department of Kasturba Medical College, Mangalore during the period of July 2008 to July 2010 of G.O.O. with chief complaints of projectile vomiting, visible gastric peristalsis or palpable distended stomach were included in this study. Cases of functional non-mechanical cause of G.O.O were excluded. Only patients of 20 years & above were included in this study. Saline load test, upper gastro-intestinal endoscopy and routine laboratory investigations done in all cases while Barium meal study was done in few cases to decide the diagnosis.
Results: Age group of 50-59 was maximum sufferer 40%, followed by age group 60-69 years (30%). Male-Female ratio was 2.3: 1. Antral carcinoma (75%) cases topped the list followed by cicatrized duodenal ulcer which was seen in 22.5% cases; only one case was due to trichobezoar.
Conclusion: This study is a clinical observational study of gastric outlet obstruction, but in vast majority of cases diagnosis can be established clinically. Males are more sufferers and antral carcinoma seems to be main causes of G.O.O. After proper diagnosis relief to patient can be given by surgical treatment. The type of procedure depends on underlying cause.
Key Words: Gastric outlet obstruction; duodenal ulcer; pyloric obstruction; antral carcinoma; trichobezoar.
References:
1.John .P Welch and Claude E Welch, Peptic Ulcer, Stomach & duodenam in Peter J Morris and Ronald A. Malt's ; Oxford text book of Surgery. Volume I First Edition. 1994.
2.Zimmerman, L.M., asnd Veitu L. : Great Ideas in the history of Surgery. Baltimore, Williams & Wilkins. 1961.
3.Welch CE, Rodkey GV, Gryska PR, A thousand operations for ulcer disease. Ann. Sug, 1986;204: 454-67.
4.Gert H. Brieger, MD, Ph.D., Historical Aspects important in the origin and development of Modern Surgical Science, in David .C Sabiston. Jr. M.D., H.Kin Liverly, M.D.„ Sabiston's Text Book Surgery, 16th Edition. W.B. Saunders Company, Philadelphia.
5.B.T. Jackson. An introduction to the history of Surgery in Kevin G Burnand Anthony. E. Young : The new Airds Companion in surgical studies. Churchill Living Stone, U.K. 1992.
6.Derek Frederickson, “Gastric Outlet Obstruction In Adults” ecapp 0504 p.utd.com 122,167.29251-3E4CF6DF34-11- 2010.
7.Mc Quaid Kenneth et al, chapter 15, gastrointestinal diosorder, JR-current medical diagnosis and treatment -2010.
8.Dallas N Shone et al “ Malignancy is the most important cause of G.O.O. in era of H2 blocker.” American Journal Of Gastroenterology2008; 90(10):1769-70 .
9.Fisher Dr, Ebert PA, Zenidena GD, Obstructing peptic ulcers results of treatment, Arch. Surg., 1967;94: 724-9.
10.Yogiram B. and Chowdary NVS. Duodenal (ulcer) stenosis in Andhra Pradesh. A 10 year study. Ind. J. Surg. 1983;12-6.
11.Kozoll D.D. and Meyer K.A., 1964, Obstructing gastroduodenal ulcers: Symptoms and signs, Arch. Surg. 89:491.
12.Schwartz ML, Humphry WE, Dunn HD, Weiland Douglas, Gastric outlet obstruction in peptic ulcer disease,an indication for surgery,Am-J surgery 1982;143:90.
Article citation:-
Ranka Kshitiz , Jain Ruchita & Jhanwar Ankur. Gastric outlet obstruction in adults: A prospective study in tertiary care hospital of Karnataka. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013, July; 32(32): 1282-1286. Available at http://www.jpbms.info.
Copyright © 2013 Ranka Kshitiz , Jain Ruchita & Jhanwar Ankur. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case study:-
*1El hag, Wafa, I, PhD. & 2Mahmoud ,Mohaned ,I H.
Affiliation:-
1Assistant professor – microbiology department, faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan
2MSc. Student, faculty of Medical Laboratory Sciences- Sudan University of Science and Technology, Sudan.
Authors’ contributions
Both author contributed equally to this paper.
Abstract:
Objectives: this study aimed to determine the frequency of human immunodeficiency virus (HIV) antibodies (IgG, IgM) among blood donors attending National Blood Transfusion Center- in Khartoum during period April 2012.
Materials & Methods: One hundred and eighty blood donors were enrolled in this study. Blood specimens collected and examined by ELISA technique (fourth generation).
Results: The anti HIV antibodies were detected among 2 (1.1%). Most of the donors examined were male176 (96.5%), young adult (21-30), and most of them were single 72 (42.5%).The study showed that there is no significant relationship between the positive results and the history of previous surgical operation, or blood transfusion because no one from the studied population had a history of blood transfusion.
Conclusion: The frequency of anti HIV antibodies among the studied population is not high, but, people working in blood transfusion center must take good care when they handle blood bags and specimens, and destroy any positive results.
Key Words: HIV, antibodies (IgG, IgM) , blood donors, ELISA technique.
References:
1.Weiss, R. A."How does HIV cause AIDS?” Science. 1993. 260 (5112): 1273–9.
2.Douek, D. C.Roederer, M., Koup, R. A. "Emerging Concepts in the ImmunopathogenesisofAIDS".Annu.Rev.Med. 2009. 60:47184.
3.WHO report.Current WHO phase of pandemic alert. 2009
4.Greener, R.AIDS and macroeconomic impact". In S, Forsyth (Ed.). State of The Art: AIDS and Economics. 2002. IAEN. pp. 49–55.
5.Palella, F. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators". N. Engl. J. Med. 1998; 338 (13): 853–60.
6.Cunningham, A.; Donaghy, H.; Harman, A.; Kim, M.; Turville, S. "Manipulation of dendritic cell function by viruses". Current opinion in microbiology. 2010;13(4): 524–9.
7.Migueles, S., Connors, M. "Long-term Nonprogressive Disease Among Untreated HIV-Infected Individuals: Clinical Implications of Understanding Immune Control of HIV". Journal of the American Medical Association. 2010. 304 (2): 194–201.
8.Schneider, M. F., Gange, S. J., Williams, C. M., Anastos, K., Greenblatt, R. M., Kingsley, L., et al. "Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984–2004". AIDS. 2005. 19 (17): 2009–18.
9.Elfaki , A. H., Eldour, A. A., Elsheikh, N. M. Sero-prevalence of immunodeficiency virus, hepatitis B and C and syphilis among blood donors at ElObeid Teaching Hospital, West Sudan Journal of Medical Science 2008;3 (4):333-8.
10.Taha, M.A. “Seroprevelance of HIV among Blood Donors” Sudan medical.J 2011:33.
11.Ogonkolo O.O., Adenaike, F.A.,Amballi, A.A., andOlokoyo,O. Prevalence of HIV positive among blood donors in Semi-Uran Nigeria , Afreican Journal of Biotechnology 2006; 5(7):553-4.
12.Zheng, Y. H., Lovsin, N. and Peterlin, B. M. "Newly identified host factors modulate HIV replication". Immunol. Lett. 2005. 97 (2): 225–34.
13.Makroo, R. N., Mohit Chowdhry, M., Bhavna, A.B., Rosamma, N.L. “Prevalence of HIV among blood donors in a tertiary care centre of north India Indian” J Med Res 2011;134:950-3.
Article citation:-
El hag, Wafa I. & Mahmoud, Mohaned I H. Frequency of HIV among blood donors attending national blood transfusion center-Khartoum,Sudan. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1362-1366. Available at http://www.jpbms.info.
Copyright © 2013 El hag, Wafa I. & Mahmoud, Mohaned I H. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:-
*1Rugmini Kamalammal and 2Jisha Susan Babu
Author’s contributions-All authors contributed equally to this paper.
Abstract:
Bronchiolitis is one of the most common lower respiratory infections in infants. There is a wide variation in treatment of bronchiolitis in different institutions and hence there is a need for standardization of existing modalities of treatment.
Aims:- To compare the efficacy of nebulised salbutamol versus adrenaline in infants admitted with bronchiolitis.
Settings and Design:- Tertiary care hospital. Randomized double blind case control trial.
Methods and Material:- Thirty infants admitted with the clinical diagnosis of bronchiolitis were included in the study. Each child received periodic doses of either nebulised salbutamol (group I) or adrenaline (group 2) and were assessed with respect to heart rate, respiratory rate, SpO2 and Respiratory Distress Assessment Instrument (RDAI).
Statistical analysis:- Student t -test
Results: In the 42nd hour and 48th hour the respiratory rates in the adrenaline group showed significant reduction as compared with the salbutamol group. There was statistically significant improvement in oxygen saturation and RDAI in the salbutamol group, when compared to adrenaline group at the 42nd hour of admission and RDAI showed further improvement at 48 hours in the same group. There was no significant difference in the improvements in heart rates between the two groups.
Conclusions:- There is definitely a benefit in relieving respiratory distress and reducing oxygen requirement with both salbutamol and adrenaline and it is more after 42 hours of treatment. Salbutamol seems to be better in terms of reduced oxygen requirement and improved RDAI score but adrenaline is found to be good in reducing respiratory rate alone.
Key words: Bronchiolitis; salbutamol; adrenaline.
References:
1.Hall CB. Respiratory syncytial virus and parainfluenza virus. New Engl J Med. 2001; 344(25):1917-28.
2.Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus among children under two years of age in a defined geographical area. Arch Dis child 2003; 88 (12) :1065-9.
3.Pelletier AJ, Mansbach JM, Camargo CA Jr . Direct medical costs of bronchiolitis hospitaliza-tions in the United States. Pediatrics. 2006 ; 118(6):2418-23.
4.Bronchiolitis in children- a national clinical guideline Nov 2006 1.1 Scottish Intercollegiate Guidelines Network. , ISBN 1 (10) 905813 01 5, ISBN (13) 978 1 905813 01.
5.Nagakumar P, Doull I. Current therapy for bronchiolitis. Arch Dis Child. 2012; 97(9):827-30.
6.Green RJ, Zar HJ, Jeena PM, Madhi SA, Lewis H. South African guideline for the diagnosis, management and prevention of acute viral bronchiolitis in children. S Afr Med J. 2010 M; 100(5):320, 322-5.
7.L Bialy, M Smith, T Bourke, L Becker. The Cochrane Library and bronchiolitis: an umbrella review (pages 939–947) . Evidence-Based Child Health: A Cochrane Review Journal2006; 1(4): 939–47.
8.Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2006; 3: CD001262 Update in: Cochrane Database Syst Rev. 2010;(12):CD001266
9.Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2011 ,15;(6):CD003123.
10.Kellner JD, Ohlsson A, Gadomski AM, Wang EEL. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis. Arch Pediatr Adolesc Med 1996; 150: 1166-72.
11.M S Ray and V Singh. Comparison of Nebulised adrenaline versus Nebulised Salbutamol in Wheeze Associated Respiratory Tract infection in Infant .Indian Padiatrics.2002; 39:12-22.
12. Lowell DI, Lister G, Von Koss, McCarthy. Wheezing in Infants: The response to adrenaline. Pediatrics. 1987; 79(6):939–45.
13.23. Sqn Ldr BM John, Sqn Ldr SK Patnaik, Col PL Prasad. Efficacy of nebulised epineph-rine versus salbutamol in hospitalised children with bronchiolitis Medical Journal Armed Forces India 2006; 62(4): 354–7.
14.Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V.Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis.J Pediatr. 1993; 122(1):145-51.
15.Hartling L, Wiebe N, Russell K, Patel H, Klassen TP.A meta-analysis of randomized con-trolled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. Arch Pediatr Adolesc Med.2003 ;157(10):957-64.
16.Schindler M. Do bronchodilators have an effect on bronchiolitis, Crit Care. 2002; 6(2): 111–2.
17.Can D, Inan G, Yendur G, Oral R, Gunay I. Salbutamol or mist in acute bronchiolitis. Acta Paediatric Jpn. 1998; 40:252–5.
18.Kristjansson S, Loprup-Carlsen KC, Wennergren G, Strannegard IL, Carlsen KH. Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers. Arch Dis Childh. 1993; 69:650–4.
19.Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM. Randomized trial of salbutamol in acute bronchiolitis. J Pediatr. 1991; 118:807–11.
20.Menon K, Sutcliffe T, Klassen TP. A randomized trial comparing the efficacy of adrenaline with salbutamol in the treatment of acute bronchiolitis. J Paediatric 1995; 126: 1004-7.
21.M R Modaressi, A Asadian, J Faghihinia, M Arashpour, F Mousavinasab. Comparison of Epinephrine to Salbutamol in Acute Bronchiolitis. Iran J Pediatr. 2012 June; 22(2): 241–4.
22.Langley JM, Smith MB, LeBlanc JC, Joudrey H, Ojah CR, Pianosi P. Racemic adrenaline compared to salbutamol in hospitalized young children with bronchiolitis. BMC Pediatrics 2005; 5:7.
Article citation:-
Rugmini Kamalammal and Jisha Susan Babu. Efficacy of nebulised adrenaline versus salbutamol in hospitalised children with bronchiolitis. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1407-1412.Available at http://www.jpbms.info
Copyright © 2013 Rugmini Kamalammal and Jisha Susan Babu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
*1Nandedkar Prerna D.,2Sonune Sanjay.,3Chitta Shrinivas S.,4Rajurkar Sampada R
Affiliation:-
1Assistant professor, 2Professor Department of biochemistry,3Junior resident, Department of physiology,4Assistant professor, Department of PSM Government medical college, Akola (M.S), India.
Abstract:
An epidural catheter even after safe insertion & Incidence of chronic kidney disease (CKD) is increasing worldwide and show poor outcome. The correct mechanism responsible for hyperlipidemia in the patients of CKD with NS is not understood. There are very few evidences showing hyperlipidemia in patients of CKD without NS. Therefore present study is undertaken to study lipid profile pattern in CKD and compare lipid profile in CKD with NS and CKD without nephrotic syndrome.
Aims: To estimate and compare lipid profile pattern in patients of CKD with NS and CKD without NS
Settings and designs: This cross sectional study was undertaken in the Department of Biochemistry of Government Medical College Nagpur, Maharashtra.
Material and method and statistical analysis: lipid profile was analyzed and compared between 50 age & sex matched CKD withNS cases (group I) and CKD without NS cases (group II) and normal healthy subjects control of age group 20-60 years using unpaired two‐tailed Student‘t’ test.
Results: Values of total cholesterol (p<0.001), triglyceride (p<0.001), LDL-C (p<0.001) and were significantly higher in CKD with NS (group I) and CKD without NS (group II) as compare to controls but values of HDL-C (p<0.001) were significantly lower compared to controls. Also, Values of total cholesterol (p<0.001), triglyceride (p<0.001), LDL-C (p<0.001) and were significantly higher in (group I) as compared to (group II) but values of HDL-C (p>0.05) were insignificant in (group I) as compared to (group II)
Conclusion: hyperlipidemia causes high cardiovascular risk and futher renal impairement in patients of CKD with NS as compared to CKD without NS.
Key words: (CKD) Chronic kidney disease; Hyperlidemia; (NS) nephrotic syndrome.
References:
1.Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D:Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
2.Kasiske BL. Hyperlipidemia in patients with chronic renal disease:Am J Kidney Dis 1998;32:142-S156.
3.Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206.
4.Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al; The Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 1989;13(Suppl):I80-I93.
5.Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
6.Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
7.Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease: J Am Soc Nephrol 1998;9(12 Suppl): S16-23.
8.IBM SPSS Statistics [computer program].Version 19.0.0. Somers (NY): IBM
9.Antonio Lacquaniti Davide Bolignano Tsimihodimos V, Dounousi E, Siamopoulos KC: Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28: 958–73.
10.Khanna UB, Nerurkar SV, Almeida AF, Taskar SP, Acharya VN:Study of hyperlipidemia in adults with nephrotic syndrome. J Postgrad Med 1985;31:140.
11.CM Chan: Hyperlipidaemia in Chronic Kidney Disease; Ann Acad Med Singapore 2005;35:31-5.
12.Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ: Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003; 84:121–4.
Article citation:-
Nandedkar Prerna D.,Sonune Sanjay., Chitta Shrinivas S., Rajurkar Sampada R. Comparative study of hyperlipidemia in patients of CKD with nephrotic syndrome and CKD without nephrotic syndrome. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1396-1399.Available at http://www.jpbms.info.
Copyright © 2013 Nandedkar Prerna D.,Sonune Sanjay.,Chitta Shrinivas S.,Rajurkar Sampada R.. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical study
*1Gulri A, 1Sood R, 2Dodwad V & 3Nagpal S
Affiliation:-
1Post graduate 2nd year, 2HOD & Professor, 3Post graduate 3rd year, Department of periodontics,I.T.S-CDSR ,Murad Nagar ,Ghaziabad,U.P, India.
Abstract:
Alendronate (ALN), an aminobisphosphonate,is known to inhibit osteoclastic bone resorption andwas proposed to have osteostimulative properties in vivo and in vitro as shown by an increase in matrix formation. The present study aims to explore the efficacy of a 1% ALNgel compared to a placebo gel as a local drug delivery system in adjunct to scaling and root planing (SRP) for the treatment of patients with chronic periodontitis.
A total of 20 sites with pocket depth of 4-6 mm were treated witha 1%ALN or placebo gel in adjunct to scaling and root planing. The ALN gel was prepared by adding ALN to a polyacrylic acid–distilled water mixture. Clinical parameters (gingival index, plaque index, probing depth [PD], and relative attachment level [RAL]) were recorded at baseline and 15 and 30 days.It was concluded that GI, PI , PPD , RAL is reduced in the test site where 1% ALN was placed in adjunct to scaling and root planning.
Key Words: Alendronate; Scaling and root planing (SRP); Gingival crevicular fluid.
References:
1.Chapple IL, Matthews JB. The role of reactive oxygenand antioxidant species in periodontal tissue destruction.Periodontol 2000 2007;43:160-232.
2.SlotsJ.Subgingivalmicroflora and periodontal disease.JClinPeriodontol 1979;6:351-82
3. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 1993;8(Suppl. 2):S565-S72.
4.Goziotis A, Sukhu B, Torontali M, DowhaniukM,Tenenbaum HC. Effects of bisphosphonates APD andHEBP on bone metabolism in vitro. Bone 1995;
16(Suppl. 4):317S-27S.
5.Tenenbaum HC, Torontali M, Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 1992;13:249-55.
6.Giuliani N, Pedrazzoni M, Negri G, Passeri G, ImpicciatoreM, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promoteearly osteoblastogenesis in young and aged mice in vivo.Bone1998;22:455-61.
7.Vitte´C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast- mediated resorption. Endocrinology 1996;137:2324-33.
8. Yaffe A, Fine N, Alt I, Binderman I. Effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. JPeriodontol 1995;66:999-1003.
9. Yaffe A, Fine N, Binderman I. Regional accelerated phenomenon in the mandible following mucoperiosteal flap surgery. J Periodontol 1994;65:79-83.
10. Yaffe A, Iztkovich M, Earon Y, Alt I, Lilov R, BindermanI. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal
flap surgery in rats. J Periodontol 1997;68:884-9.
11. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing:Literature review and a case report. J Periodontol2007;78:584-94.
12. Silness J, Lo¨e H. Periodontal disease in pregnancy. II.Correlation between oral hygiene and periodontal condition.ActaOdontolScand1964;22:121-35.
13. Lo¨eH ,Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. ActaOdontolScand 1963;21:533-51.
14.Reddy GT, Kumar TM, Veena KM. Formulation and evaluation of alendronate sodium gel for the treatment of bone resorptive lesions in periodontitis. Drug Deliv 2005;12:217-22.
15. Lin JH, Chen IW, deLuna FA.On the absorption of alendronate in rats.JPharmSci1994;83:1741-46.
16. Fleisch H. Bisphosphonates: Mechanisms of action.Endocr Rev 1998; 19:80-100.
17. Srisubut S, Teerakapong A, Vattraphodes T, TaweechaisupapongS. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats.OralSurg Oral Med Oral Pathol Oral Radiol Endod2007;104:e11-e16.
18.Luckman SP, Coxon FP, Ebetino FH, Russell RGG,Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structureactivity relationships inmacrophages. J Bone Miner Res 1998;13:1668-78.
19.Rocha M, Nava LE, Va´zquez de la Torre C, Sa´nchez-Ma´ rin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. JPeriodontol2001;72:204-09.
20.Brunsvold MA, Chaves ES, Kornman KS, Aufdemort TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992;63:825-30.
21.Needleman IG, Pandya NV, Smith SR, Foyle DM. The role of antibiotics in the treatment of periodontitis J Periodontol • January 2012 Sharma, Pradeep17(part 2 – controlled drug delivery). Eur J ProsthodontRestor Dent 1995;3:111-17.
Article citation:-
Gulri A, Sood R ,Dodwad V & Nagpal S. Clinical efficacy of 1% alendronate gel as a local drug delievery system in the treatment of chronic periodontitis. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1343-1347. Available at http://www.jpbms.info.
Copyright © 2013 Gulri A, Sood R, Dodwad V & Nagpal S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.